Compare · ARGX vs GLUE
ARGX vs GLUE
Side-by-side comparison of argenx SE (ARGX) and Monte Rosa Therapeutics Inc. (GLUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and GLUE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 38.1x GLUE ($1.44B).
- Over the past year, ARGX is up 51.2% and GLUE is up 243.6% - GLUE leads by 192.3 points.
- GLUE has been more active in the news (8 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 11 for GLUE).
- Company
- argenx SE
- Monte Rosa Therapeutics Inc.
- Price
- $882.63-1.03%
- $16.99+3.85%
- Market cap
- $54.76B
- $1.44B
- 1M return
- +12.11%
- -14.24%
- 1Y return
- +51.24%
- +243.58%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 5
- 8
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest GLUE
- President & CEO Warmuth Markus sold $106,253 worth of shares (5,466 units at $19.44) as part of a pre-agreed trading plan, decreasing direct ownership by 0.91% to 594,538 units (SEC Form 4)
- Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $119,220 worth of shares (6,000 units at $19.87) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Champoux Jennifer exercised 2,175 shares at a strike of $3.98 and sold $43,500 worth of shares (2,175 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Champoux Jennifer exercised 2,176 shares at a strike of $3.98 and sold $41,344 worth of shares (2,176 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)
- Director Manning Anthony M. exercised 10,000 shares at a strike of $4.16 and sold $180,100 worth of shares (10,000 units at $18.01) (SEC Form 4)
- SEC Form 144 filed by Monte Rosa Therapeutics Inc.
- Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.